Rogocekib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Rogocekib (development code CTX-712) is an investigational oral small-molecule inhibitor of CDC2-like kinases (CLKs), primarily targeting CLK2 with high potency (IC 50 of 1.4 nM). It is being developed as a potential treatment for certain cancers, particularly hematologic malignancies.
Rogocekib (development code CTX-712) is an investigational oral small-molecule inhibitor of CDC2-like kinases (CLKs), primarily targeting CLK2 with high potency (IC 50 of 1.4 nM). It is being developed as a potential treatment for certain cancers, particularly hematologic malignancies.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329976259 under CC BY-SA 4.0; modifications have been made.